HIV Meds Can Benefit Positive Gay Meth and Cocaine Users

So you can continue to enjoy a vein full of crystal meth and a nose full of cocaine--and still benefit from Truvada and all the other lifesavingtreatments.

A green light for Friends of Tina?

You be the  judge



HIV-positive men who have sex with men (MSM) and who use stimulants such as methamphetamine or cocaine can benefit significantly from antiretroviral (ARV) treatment. Publishing their findings in the Journal of Acquired Immune Deficiency Syndromes, researchers at the University of California, San Francisco (UCSF) conducted a study of 1,313 HIV-positive MSM who started ARVs while participating in the Multicenter AIDS Cohort Study. The data on the participants was collected between 1996 and 2012.

A total of 341 of the men reported using stimulants. The researchers found no significant correlation between any level of stimulant use and risk of death from any cause. Nor did an analysis that separately examined AIDS-related deaths and non-AIDS-related deaths indicate any correlation to stimulant use.

Profiteering with PrEP (PreExposure Prophylaxis). Gilead pharmaceutical company's toxic Truvada for so-called HIV

by Terry Michael, September 30, 2014

I trace how a supplemental use for Gilead's HIV chemotherapy went from confirmation-biased clinical trials, funded by Dr. Anthony Fauci, NIH/NIAID director; to approval by the FDA, in a corrupt "user fee" (funded by Gilead) fast-tracked process, just in time for Fauci to announce it at the International AIDS Society "XIX AIDS Conference" in Washington, DC, in July 2012; to the CDC's  compliant  endorsement in May 2014; and now is being touted by a science-uninformed mass media and gay press, heavily promoted by the Gilead public relations machine.

America’s AIDS czar for almost 30 years, Dr. Anthony Fauci has promoted and shepherded human experimental research that has exposed HIV negative Third World men and women to toxic chemotherapy, many already health-challenged from lack of clean water, poor sanitation, malnutrition and old diseases like tuberculosis and malaria. The experiments were to demonstrate “Pre-Exposure Prophylaxis” (PrEP) for the anti-viral drug Truvada. Like other nucleoside analogs, Truvada has well-assessed adverse (“side”) effects. Funded with tax dollars and non-profit grants, including tens of millions from Fauci’s National Institute of Allergy and Infectious Diseases, as well as from the CDC and USAID, studies have accrued to the sole benefit of a politically well- connected U.S. drug corporation, Gilead, the only company to “donate” pills for the clinical trials. 

When PrEP was discussed initially in mainstream media, including in a New York Times articlepublished January 22, 2006 (later critically reviewed by independent journalist Liam Scheff), human guinea pigs, almost all impoverished Third World subjects, were already in early phase trials, designed to produce results that would allow Gilead eventually to seek FDA approval for re- purposing its “Viread” but later only its “Truvada” chemotherapy for use by HIV antibody negative Americans, for theoretical protection from a virus proclaimed by the U.S. government in 1984 as a discrete pathogen responsible for the amorphous health condition described since 1982 as “acquired immune deficiency syndrome,” or “AIDS.” Under patent protection until 2021, Truvada remains more profitable for Gilead than Viread, for which a generic can be sold as early as December 2016.